Session Details
[27-64-pm2]Drug discovery, structure-activity relationship 1
Fri. Mar 27, 2026 3:30 PM - 5:30 PM JST
Fri. Mar 27, 2026 6:30 AM - 8:30 AM UTC
Fri. Mar 27, 2026 6:30 AM - 8:30 AM UTC
Room 64 (Collaboration Commons, RINPUKAN [1F]) (3)
Discusser: Minoru Ishikawa, Makoto Oba
[27-64-pm2-27S]Virtual screening and validation of AGEs inhibitors based on large models
○Rui Liang1, Li Fan1, Haomiao Ma1, Zhiru Li1, Ruofei Li1, Zhuo Cheng1, Yan Pan1, Bo Xian1 (1. Grad. Sch. Med. Sci., UESTC.)
[27-64-pm2-28S]Synthesis of 4’-ethynylpseudouridine and 4’-cyanopseudouridine as anti-SARS-CoV-2 agents
○Ami Sato1, Nobuyo Kuwata2, Shinichiro Hattori2, Hiroaki Mitsuya2, Kiju Konno1 (1. International Univ. Health And Welfare, 2. National Institute of Global Health and Medicine)
[27-64-pm2-29S]Structure-Activity Relationship of Glutathione-Triggered Prodrug of STING Agonist
○Ryo Nishimura1, Takayuki Ohkuri2, Radhakrishnam Raju Ruddarraju1, Kazuki Yamamoto1, Satoshi Ichikawa1 (1. Faculty of Pharmaceutical Sciences, Hokkaido Univ., 2. Department of Pathology, Asahikawa Medical Univ.)
[27-64-pm2-30S]Synthesis of 4’-fluorocordycepin targeting SARS-CoV-2 RNA porymerase
○Nanaka Shoro1, Nobuyo Kuwata2, Shinichiro Hattori2, Hiroaki Mitsuya2, Kiju Konno1 (1. International Univ. of Health and Welfare, 2. National Institute of Global Health and Medicine)
[27-64-pm2-31S]Synthesis and structure-activity relationships of fentanyl derivatives
○Koki Yagi1, Hironobu Arita1, Kohei Sezaki1, Haruka Sakata1, Mizuha Nishimoto1, Masahiko Funada2, Kenichi Tomiyama3, Hidetsugu Tabata4, Kayo Nakamura1, Tetsuta Oshitari4, Hideaki Natsugari5, Hideyo Takahashi1 (1. Pharm. Sci., Tokyo Univ. Sci., 2. Pharm. Sci., Shonan Univ. Med. Sci., 3. National Center of Neurology and Psychiatry, 4. Pharm. Sci., Teikyo Univ., 5. Pharm. Sci., Niigata Univ. Pharm. & Appl. Life Sci.)
[27-64-pm2-32S]Evaluation of the effect of changes in the hydrophobic face angle of amphipathic helical peptides on lipid membranes
○Mai Ueki1, Takuma Kato1, Mitsunobu Doi1, Akiko Asano1 (1. Facul. Pharm. Osaka Med. Pharm. Univ.)
[27-64-pm2-33S]Synthesis and structure-activity relationship studies of anti-inflammatory iridoids from Tabebuia avellanedae
○Yuga Kotera1, Aozora Sano1, Mitsuaki Yamashita1, Youichi Fukuda1, Seiji Ohno1, Akira Iida1 (1. Grad. Sch. Agri. SCI., Kindai Univ.)
[27-64-pm2-34S]Creation of antitrypanosomal compounds based on lignan skeletons
○Marina Tada1, Takehiro Nishimura1, Yuka Tani1, Haruhisa Kikuchi1 (1. Fac. Pharm., Keio Univ.)
[27-64-pm2-35S]Synthesis of Carbovir derivatives with 7-deazaadenine structure as anti-adenovirus agents
○Kyoko Hara1, Maki Sawada1, Shion Nishizuka1, Eri Hasegawa1, Takuya Ogawa1, Kiju Konno1 (1. International Univ. Health And Welfare)
[27-64-pm2-36S]Development of anti-adenovirus infections disease agentsStructure-activity relationship studies of nucleobase structures with Carbovir as a lead compound
○MAKI SAWADA1, Kyouko Hara1, Shion Nishizuka1, Eri Hasegawa1, Takuya Ogawa1, Kiju Konno1 (1. International Univ. Health and Welfare)
[27-64-pm2-37S]Synthesis of 4’-fluoro-pseudouridine and 4’-azido-pseudouridine targeting anti-SARS-CoV-2 activity
○Mai Hirano1, Toru Kogawara1, Nobuyo Kuwata2, Shinichiro Hattori2, Hiroaki Mitsuya2, Kiju Konno1 (1. International Univ. Health And Welfare, 2. National Institute of Global Health and Medicine)
[27-64-pm2-38S]Development of a novel assay system targeting Saprolegnia parasitica and evaluation of the biological activities of oridamycin analogues.
○Miyuu Mori1, Yui Asano1, Naoto Yamasaki2, Yoshinori Asakawa1, Hirofumi Yamamoto1 (1. Fac. Pharm. Sci., Tokushima Bunri Univ., 2. Grad. Sch. Pharm. Sci., Nagoya Univ.)